Author:
Tao T. T.,Lin X. H.,Tang S. J.,Gui W. W.,Zhu W. F.,Li H.
Abstract
AbstractBackgroundMetabolic syndrome (MetS) is a complex of interrelated risk factors, including central adiposity, increased blood pressure, hyperglycemia, elevated triglyceride levels and low high-density lipoprotein. Few studies have reported the genetic variants in theSirt1andNrf2genes (Sirt1rs7895833 A > G,Sirt1rs2273773 C > T andNrf2rs6721961 C > A) that increase the risk of type 2 diabetes mellitus and are correlated with some glycemic and metabolic traits in the Chinese Han population.MethodsOur study recruited 141 individuals with MetS and 549 individuals without MetS to investigate the associations between three single nucleotide polymorphisms (SNPs) ofSirt1andNrf2and the risk of MetS in a Chinese Han population using the PCR-CTPP method.ResultsThis research showed that the risk of MetS was 2.41 times higher for the AA genotype (P = 0.038) and 1.94 times higher for the AG genotype (P = 0.016) compared with carriers of the GG genotype. The serum levels of low-density lipoprotein cholesterol and HOMA-IR were significantly higher (P < 0.05) in carriers of the AA genotype ofSirt1rs7895833 than in carriers of the AG and GG genotypes in the general population. The serum level of total cholesterol in the AA genotype was lower (P = 0.033) than that in the other two genotypes. However, the genotype frequencies ofSirt1rs2273773 andNrf2rs6721961 in the MetS group were not significantly different from those in the control subjects, and those two genetic variants were not correlated with metabolic traits.ConclusionsThese results underscore the contributions of SNPs ofSirt1rs7895833 to MetS susceptibility as well as glycemic and metabolic traits in a Chinese population.
Funder
National Natural Science Foundation of China
Natural Science Foundation of Zhejiang Province
Publisher
Springer Science and Business Media LLC
Subject
General Medicine,Endocrinology, Diabetes and Metabolism
Reference27 articles.
1. Kastorini CM, Panagiotakos DB, Georgousopoulou EN, et al. Metabolic syndrome and 10-year cardiovascular disease incidence: the ATTICA study. Nutr Metab Cardiovasc Dis. 2016;26(3):223–31.
2. Pucci G, Alcidi R, Tap L, Battista F, Mattace-Raso F, Schillaci G. Sex- and gender-related prevalence, cardiovascular risk and therapeutic approach in metabolic syndrome: a review of the literature. Pharmacol Res. 2017;120:34–42.
3. Lu J, Wang L, Li M, et al. Metabolic syndrome among adults in China: The 2010 China Noncommunicable Disease Surveillance. J Clin Endocrinol Metab. 2017;102(2):507–15.
4. Povel CM, Boer JM, Reiling E, Feskens EJ. Genetic variants and the metabolic syndrome: a systematic review. Obes Rev. 2017;12(11):952–67.
5. Luo J, Nikolaev AY, Imai S-I, Chen D, Fei Su, et al. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell. 2001;107(2):137–48.